Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue
No Thumbnail
Authors
Babić, TamaraLygirou, Vasiliki
Rosić, Jovana
Miladinov, Marko
Rom, Aleksandra Djikic
Baira, Eirini
Stroggilos, Rafael
Pappa, Eftychia
Zoidakis, Jerome
Krivokapić, Zoran
Nikolić, Aleksandra
Article (Published version)
Metadata
Show full item recordAbstract
Purpose In the search for candidate predictive biomarkers to evaluate response to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer, only a few studies report proteomic profiles of tumor tissue before and after nCRT. The aim of our study was to determine differentially expressed proteins between responders and non-responders before and after the therapy in order to identify candidate molecules for prediction and follow-up of response to nCRT. Experimental Design The study has included tissue sections of rectal tumor and non-tumor mucosa from five responders and five non-responders taken before and after nCRT from patients with locally advanced rectal cancer. Extracted proteins were analyzed by LC-MS/MS analysis followed by a set of bioinformatics analyses. Result Proteomics analysis provided a mean of approximately 1050 protein identifications per sample. A comparison of proteomic profiles between responders and non-responders has identified 18 differentially expressed proteins. Pa...thway analysis demonstrated high metabolic activity in non-responders' tumors before nCRT, indicating the presence of intrinsic chemoradioresistance in these subjects. Two proteins associated with poor prognosis in colorectal cancer, ADAM10 and CAD, were identified as candidate predictive biomarkers as they were present in non-responders only. Conclusions and Clinical Relevance Shortlisted proteins from our study should be further validated as candidate biomarkers for response to routinely applied nCRT protocols.
Keywords:
rectal cancer / proteomics / neoadjuvant chemoradiotherapy / biomarkerSource:
Proteomics Clinical Applications, 2022Publisher:
- Wiley-V C H Verlag Gmbh, Weinheim
Funding / projects:
- COST (European Cooperation in Science and Technology) [CA17118]
- Strategic Project of the Serbian Academy of Sciences and Arts Molecular basis of response to chemioradiotherapy in rectal cancer - MOHERATEKA [F-69]
DOI: 10.1002/prca.202100116
ISSN: 1862-8346
PubMed: 35997210
WoS: 000850487700001
Scopus: 2-s2.0-85137501697
Collections
Institution/Community
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Babić, Tamara AU - Lygirou, Vasiliki AU - Rosić, Jovana AU - Miladinov, Marko AU - Rom, Aleksandra Djikic AU - Baira, Eirini AU - Stroggilos, Rafael AU - Pappa, Eftychia AU - Zoidakis, Jerome AU - Krivokapić, Zoran AU - Nikolić, Aleksandra PY - 2022 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1521 AB - Purpose In the search for candidate predictive biomarkers to evaluate response to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer, only a few studies report proteomic profiles of tumor tissue before and after nCRT. The aim of our study was to determine differentially expressed proteins between responders and non-responders before and after the therapy in order to identify candidate molecules for prediction and follow-up of response to nCRT. Experimental Design The study has included tissue sections of rectal tumor and non-tumor mucosa from five responders and five non-responders taken before and after nCRT from patients with locally advanced rectal cancer. Extracted proteins were analyzed by LC-MS/MS analysis followed by a set of bioinformatics analyses. Result Proteomics analysis provided a mean of approximately 1050 protein identifications per sample. A comparison of proteomic profiles between responders and non-responders has identified 18 differentially expressed proteins. Pathway analysis demonstrated high metabolic activity in non-responders' tumors before nCRT, indicating the presence of intrinsic chemoradioresistance in these subjects. Two proteins associated with poor prognosis in colorectal cancer, ADAM10 and CAD, were identified as candidate predictive biomarkers as they were present in non-responders only. Conclusions and Clinical Relevance Shortlisted proteins from our study should be further validated as candidate biomarkers for response to routinely applied nCRT protocols. PB - Wiley-V C H Verlag Gmbh, Weinheim T2 - Proteomics Clinical Applications T1 - Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue DO - 10.1002/prca.202100116 ER -
@article{ author = "Babić, Tamara and Lygirou, Vasiliki and Rosić, Jovana and Miladinov, Marko and Rom, Aleksandra Djikic and Baira, Eirini and Stroggilos, Rafael and Pappa, Eftychia and Zoidakis, Jerome and Krivokapić, Zoran and Nikolić, Aleksandra", year = "2022", abstract = "Purpose In the search for candidate predictive biomarkers to evaluate response to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer, only a few studies report proteomic profiles of tumor tissue before and after nCRT. The aim of our study was to determine differentially expressed proteins between responders and non-responders before and after the therapy in order to identify candidate molecules for prediction and follow-up of response to nCRT. Experimental Design The study has included tissue sections of rectal tumor and non-tumor mucosa from five responders and five non-responders taken before and after nCRT from patients with locally advanced rectal cancer. Extracted proteins were analyzed by LC-MS/MS analysis followed by a set of bioinformatics analyses. Result Proteomics analysis provided a mean of approximately 1050 protein identifications per sample. A comparison of proteomic profiles between responders and non-responders has identified 18 differentially expressed proteins. Pathway analysis demonstrated high metabolic activity in non-responders' tumors before nCRT, indicating the presence of intrinsic chemoradioresistance in these subjects. Two proteins associated with poor prognosis in colorectal cancer, ADAM10 and CAD, were identified as candidate predictive biomarkers as they were present in non-responders only. Conclusions and Clinical Relevance Shortlisted proteins from our study should be further validated as candidate biomarkers for response to routinely applied nCRT protocols.", publisher = "Wiley-V C H Verlag Gmbh, Weinheim", journal = "Proteomics Clinical Applications", title = "Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue", doi = "10.1002/prca.202100116" }
Babić, T., Lygirou, V., Rosić, J., Miladinov, M., Rom, A. D., Baira, E., Stroggilos, R., Pappa, E., Zoidakis, J., Krivokapić, Z.,& Nikolić, A.. (2022). Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue. in Proteomics Clinical Applications Wiley-V C H Verlag Gmbh, Weinheim.. https://doi.org/10.1002/prca.202100116
Babić T, Lygirou V, Rosić J, Miladinov M, Rom AD, Baira E, Stroggilos R, Pappa E, Zoidakis J, Krivokapić Z, Nikolić A. Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue. in Proteomics Clinical Applications. 2022;. doi:10.1002/prca.202100116 .
Babić, Tamara, Lygirou, Vasiliki, Rosić, Jovana, Miladinov, Marko, Rom, Aleksandra Djikic, Baira, Eirini, Stroggilos, Rafael, Pappa, Eftychia, Zoidakis, Jerome, Krivokapić, Zoran, Nikolić, Aleksandra, "Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue" in Proteomics Clinical Applications (2022), https://doi.org/10.1002/prca.202100116 . .